Fundraising Fox
Hilltop Bio
Norwood, US · Founded 2018 · 21 employees on LinkedIn · 6 known investors
Find your way into Hilltop Bio
Each arrow is one introduction. Sign up to fill in the first one.
Ask Julien L. Pham to introduce you to Amanda Drobnis
You →Julien · together at Hilltop Bio →Amanda
Ask Jamie Chen to introduce you to Mark Williams
You →Jamie · together at Hilltop Bio →Mark
Sign up to find every way you can get introduced to Hilltop Bio
- Your email: who you already know at Hilltop Bio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Hilltop Bio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.
Founders & leadership
Board
Investors · 6
How we know: the VCSheet dataset · Not right? Tell us
How we know: RevUp Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7.8M disclosed across 5 rounds · 2019–2024
▶$5.3MraisedMar 2025 · 73 investors · BiotechnologyRule 506(b)
- Mark WilliamsExecutive Officer, Director
- Jessica McLearDirector
- Alan WatsonDirector
- Denise BeversDirector
- Amanda DrobnisExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $5.3M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$723.5KraisedApr 2023 · 42 investors · BiotechnologyRule 506(b)
- Amanda DrobnisExecutive Officer, Director
- Alan WatsonDirector
- Denise BeaversDirector
- Mark WilliamsDirector
- Jessica McLearDirector
- Offering amount
- $1M
- Amount sold
- $723.5K
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$866.3KraisedOct 2021 · 67 investors · BiotechnologyRule 506(b)
- Mark WilliamsExecutive Officer, Director
- Jessica McLearDirector
- Denise BeversDirector
- Alan WatsonDirector
- Amanda DrobnisExecutive Officer, Director
- Offering amount
- $1.4M
- Amount sold
- $866.3K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$149.7KraisedMay 2020 · 21 investors · BiotechnologyRule 506(b)
- Denise BeversDirector
- Jill WittelsDirector
- Amanda DrobnisExecutive Officer, Director
- Jessica McLearDirector
- Mark WilliamsExecutive Officer, Director
- Offering amount
- $450K
- Amount sold
- $149.7K
- First sale
- May 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$750.9KraisedJul 2019 · 48 investors · BiotechnologyRule 506(b)
- Mark WilliamsExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $750.9K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Hilltop Bio do?
- Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.
- Who are Hilltop Bio's investors?
- Hilltop Bio's investors include Band of Angels, Beacon Angels, Launchpad Venture Group, RevUp Capital, Walnut Venture Associates, Golden Seeds.
- How much funding has Hilltop Bio raised?
- Hilltop Bio has disclosed $7.8M raised across 5 rounds.
- Where is Hilltop Bio headquartered?
- Hilltop Bio is headquartered in Norwood, US.